BRISTOL-MYERS SQUIBB COMPANY Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net of $5.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet · last filed 2018-02-13
- BRISTOL-MYERS SQUIBB COMPANY other than temporary impairment losses, investments, portion recognized in earnings, net for the quarter ending 2016-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY other than temporary impairment losses, investments, portion recognized in earnings, net for the quarter ending 2016-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY other than temporary impairment losses, investments, portion recognized in earnings, net for the quarter ending 2016-06-30 was $45.00M.
- BRISTOL-MYERS SQUIBB COMPANY other than temporary impairment losses, investments, portion recognized in earnings, net for fiscal 2017 was $5.00M, a 88.89% decline from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY other than temporary impairment losses, investments, portion recognized in earnings, net for fiscal 2016 was $45.00M.
| Period end | Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net 3 month | Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net 6 month | Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net 9 month | Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net 12 month |
|---|---|---|---|---|
| 2017-12-31 | $5.00M 10-K · filed 2018-02-13 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $0.00 derived: sum of 2 quarters · filed 2018-02-13 | $45.00M derived: sum of 3 quarters · filed 2018-02-13 | $45.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $45.00M derived: sum of 2 quarters · filed 2017-10-26 | $45.00M 10-Q · filed 2017-10-26 | |
| 2016-06-30 | $45.00M 10-Q · filed 2017-07-27 | $45.00M 10-Q · filed 2017-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |